Phibro Animal Health Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US71742Q1067
USD
40.77
0.09 (0.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Phibro Animal Health Corp. stock-summary
stock-summary
Phibro Animal Health Corp.
Pharmaceuticals & Biotechnology
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. The Company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. The Company's Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Company Coordinates stock-summary
Company Details
300 Frank W Burr Blvd Ste 21 Fl 3 , TEANECK NJ : 07666
stock-summary
Tel: 1 201 3297300
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 60 Schemes (48.84%)

Foreign Institutions

Held by 85 Foreign Institutions (7.85%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jack Bendheim
Chairman of the Board, President, Chief Executive Officer, Director
Mr. Jonathan Bendheim
Director and President, MACIE Region and General Manager of Israel Operations
Mr. Daniel Bendheim
Executive Vice President, Corporate Strategy and Director
Mr. Gerald Carlson
Independent Director
Mr. E. Thomas Corcoran
Independent Director
Mr. Sam Gejdenson
Independent Director
Ms. Mary Malanoski
Independent Director
Ms. Carol Wrenn
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
379 Million
(Quarterly Results - Jun 2025)
Net Profit:
17 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,598 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.22%

stock-summary
Debt Equity

2.28

stock-summary
Return on Equity

18.91%

stock-summary
Price to Book

5.59